Amplification Clinical Trials in Nashville, Tennessee

7 recruitingNashville, Tennessee

Showing 17 of 7 trials

Recruiting
Phase 2

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc90 enrolled42 locationsNCT06995677
Recruiting
Phase 2

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

Solid Tumors Harboring MET Amplification
AbbVie100 enrolled33 locationsNCT07196644
Recruiting
Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 1

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

Non-small Cell Lung CancerHER2Advanced Solid Tumor, Adult+3 more
Cogent Biosciences, Inc.100 enrolled6 locationsNCT07361562
Recruiting
Phase 1

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Solid TumorsMetastatic Hepatocellular CarcinomaAdvanced Solid Tumors+11 more
Tyra Biosciences, Inc100 enrolled16 locationsNCT06915753
Recruiting
Phase 1

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Colorectal, CancerSquamous Cell Carcinoma of Head and NeckHead and Neck Squamous Cell Carcinoma+8 more
Bicara Therapeutics292 enrolled20 locationsNCT04429542
Recruiting
Phase 1Phase 2

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

CholangiocarcinomaAdvanced Solid TumorsIntrahepatic Cholangiocarcinoma (Icc)+9 more
Cogent Biosciences, Inc.110 enrolled15 locationsNCT06777316